Michaelis Martin, Köhler Nezira, Reinisch Alexander, Eikel Daniel, Gravemann Ute, Doerr Hans Wilhelm, Nau Heinz, Cinatl Jindrich
Institut für Medizinische Virologie, Klinikum der J.W. Goethe-Universität, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany.
Biochem Pharmacol. 2004 Aug 1;68(3):531-8. doi: 10.1016/j.bcp.2004.04.013.
Valproic acid (2-propylpentanoic acid, VPA), an effective inhibitor of histone deacetylases (HDAC) is used for the treatment of epilepsia. In this study, structure-activity relationships for the action of structurally modified VPA derivatives on human cytomegalovirus (HCMV) replication and HDAC inhibition were defined. Pretreatment of human foreskin fibroblasts with VPA (0.125-1mM) caused a concentration-dependent increase of HCMV immediate early and antigen late antigen expression. Structure-activity relationships of VPA derivatives for HCMV stimulation were compared to those for teratogenic action and those for HDAC inhibition. Side chain elongation and introduction of a triple bond in 4-position of the other chain caused teratogenicity, stimulated HCMV replication, and increased HDAC inhibition, as demonstrated by enhanced levels of acetylated histones. Teratogenic VPA derivatives with a branched chain in 3-position as well as a non-teratogenic anticonvulsive active VPA derivative did not stimulate HCMV or accumulation of acetylated histones. This demonstrates a strict correlation between inhibition of HDAC and increased HCMV replication.
丙戊酸(2-丙基戊酸,VPA)是一种有效的组蛋白去乙酰化酶(HDAC)抑制剂,用于治疗癫痫。在本研究中,确定了结构修饰的VPA衍生物对人巨细胞病毒(HCMV)复制和HDAC抑制作用的构效关系。用人包皮成纤维细胞预先处理VPA(0.125 - 1mM)导致HCMV立即早期和抗原晚期抗原表达呈浓度依赖性增加。将VPA衍生物对HCMV刺激的构效关系与致畸作用和HDAC抑制的构效关系进行了比较。侧链延长以及在另一条链的4位引入三键会导致致畸性,刺激HCMV复制,并增加HDAC抑制,这通过乙酰化组蛋白水平的提高得到证明。在3位具有支链的致畸性VPA衍生物以及非致畸性抗惊厥活性VPA衍生物均未刺激HCMV或乙酰化组蛋白的积累。这证明了HDAC抑制与HCMV复制增加之间存在严格的相关性。